EA201170155A1 - Специфические антагонисты рецептора fgf-r4 - Google Patents

Специфические антагонисты рецептора fgf-r4

Info

Publication number
EA201170155A1
EA201170155A1 EA201170155A EA201170155A EA201170155A1 EA 201170155 A1 EA201170155 A1 EA 201170155A1 EA 201170155 A EA201170155 A EA 201170155A EA 201170155 A EA201170155 A EA 201170155A EA 201170155 A1 EA201170155 A1 EA 201170155A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
fgf
specific antagonists
antagonists
inhibit
Prior art date
Application number
EA201170155A
Other languages
English (en)
Other versions
EA021580B1 (ru
Inventor
Николя Борен
Пьер-Франсуа Берн
Франсис БЛАНШ
Франсуаз Боно
Беатрис Камерон
Тарик ДАБДУБИ
Корантен Эрбер
Венсан Миколь
Элизабет Реми
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA201170155A1 publication Critical patent/EA201170155A1/ru
Publication of EA021580B1 publication Critical patent/EA021580B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Изобретение относится к молекулам, являющимся специфическими антагонистами рецептора FGF-R4 и позволяющим ингибировать активность этого рецептора. Эти антагонисты представляют собой, в частности, антитела, специфически направленные к рецептору FGF-R4 и позволяющие ингибировать активность указанного рецептора. Изобретение относится также к терапевтическому применению таких антител предпочтительно в области ангиогенеза и в лечении некоторых видов рака.
EA201170155A 2008-07-08 2009-07-07 Применение антитела, специфичного к рецептору fgf-r4 EA021580B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803888A FR2933702A1 (fr) 2008-07-08 2008-07-08 Antagonistes specifiques du recepteur fgf-r4
PCT/FR2009/051343 WO2010004204A2 (fr) 2008-07-08 2009-07-07 Antagonistes specifiques du recepteur fgf-r4

Publications (2)

Publication Number Publication Date
EA201170155A1 true EA201170155A1 (ru) 2011-08-30
EA021580B1 EA021580B1 (ru) 2015-07-30

Family

ID=40626849

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201401107A EA201401107A1 (ru) 2008-07-08 2009-07-07 Специфические антагонисты рецептора fgf-r4
EA201170155A EA021580B1 (ru) 2008-07-08 2009-07-07 Применение антитела, специфичного к рецептору fgf-r4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201401107A EA201401107A1 (ru) 2008-07-08 2009-07-07 Специфические антагонисты рецептора fgf-r4

Country Status (38)

Country Link
US (1) US20110150903A1 (ru)
EP (1) EP2315781B1 (ru)
JP (2) JP5726731B2 (ru)
KR (1) KR20110028536A (ru)
CN (2) CN102149730B (ru)
AR (1) AR072699A1 (ru)
AU (1) AU2009267834B2 (ru)
BR (1) BRPI0915660A2 (ru)
CA (1) CA2730300A1 (ru)
CL (1) CL2011000047A1 (ru)
CO (1) CO6440535A2 (ru)
CR (1) CR11868A (ru)
CY (1) CY1116847T1 (ru)
DK (1) DK2315781T3 (ru)
DO (1) DOP2011000005A (ru)
EA (2) EA201401107A1 (ru)
EC (1) ECSP11010748A (ru)
ES (1) ES2544761T3 (ru)
FR (1) FR2933702A1 (ru)
HK (1) HK1159133A1 (ru)
HN (1) HN2011000074A (ru)
HR (1) HRP20150836T1 (ru)
HU (1) HUE027221T2 (ru)
IL (1) IL210516A0 (ru)
MA (1) MA32547B1 (ru)
MX (1) MX2011000328A (ru)
NI (1) NI201100012A (ru)
NZ (2) NZ602905A (ru)
PE (1) PE20110313A1 (ru)
PL (1) PL2315781T3 (ru)
PT (1) PT2315781E (ru)
SG (1) SG10201403751XA (ru)
SI (1) SI2315781T1 (ru)
TW (1) TW201006492A (ru)
UA (1) UA107782C2 (ru)
UY (1) UY31970A (ru)
WO (1) WO2010004204A2 (ru)
ZA (1) ZA201100209B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34291B1 (fr) * 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP3050899B1 (en) * 2010-09-27 2019-09-04 Janssen Biotech, Inc. Antibodies binding human collagen ii
JP2014516511A (ja) * 2011-04-07 2014-07-17 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ４抗体及び使用方法
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
WO2014105849A1 (en) * 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
US9611319B2 (en) 2013-03-12 2017-04-04 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
WO2015107171A1 (en) * 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody
BR112016017248A8 (pt) 2014-01-24 2018-04-17 Ngm Biopharmaceuticals Inc anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
CN104177492B (zh) * 2014-07-21 2017-02-22 暨南大学 FGFR2c胞外段类似物及其编码基因与应用
US10358498B2 (en) * 2014-08-11 2019-07-23 Daiichi Sankyo Europe Gmbh Human anti-FGFR4 antibody
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6695353B2 (ja) 2015-03-25 2020-05-20 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
EP3095465A1 (en) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
CN109071659B (zh) 2016-02-10 2022-06-10 生物发明国际股份公司 人抗fgfr4抗体和索拉非尼的组合
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
PT3534902T (pt) 2016-11-02 2022-12-07 Novartis Ag Combinações de inibidores de fgfr4 e quelantes de ácidos biliares
JP7265476B2 (ja) * 2016-11-22 2023-04-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ１を対象とするモノクローナル抗体
EP3444275A1 (en) * 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN109725159B (zh) * 2018-12-28 2021-10-08 江苏众红生物工程创药研究院有限公司 人β2-微球蛋白的定量检测试纸卡与临床应用
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU767394C (en) * 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
AU2007254005B2 (en) * 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
AU2007315211B2 (en) * 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
MX2009009574A (es) * 2007-03-09 2009-09-16 Novartis Ag Tratamiento de melanoma.

Also Published As

Publication number Publication date
CO6440535A2 (es) 2012-05-15
EA201401107A1 (ru) 2015-05-29
US20110150903A1 (en) 2011-06-23
IL210516A0 (en) 2011-03-31
NI201100012A (es) 2011-07-20
CY1116847T1 (el) 2017-03-15
MA32547B1 (fr) 2011-08-01
CN103784954A (zh) 2014-05-14
AU2009267834B2 (en) 2014-10-23
CN102149730B (zh) 2014-03-26
EP2315781B1 (fr) 2015-05-06
HN2011000074A (es) 2013-01-28
CL2011000047A1 (es) 2011-07-08
JP5726731B2 (ja) 2015-06-03
TW201006492A (en) 2010-02-16
DK2315781T3 (en) 2015-08-10
JP2015057398A (ja) 2015-03-26
UY31970A (es) 2010-02-26
CA2730300A1 (fr) 2010-01-14
UA107782C2 (ru) 2015-02-25
WO2010004204A2 (fr) 2010-01-14
HK1159133A1 (en) 2012-07-27
EA021580B1 (ru) 2015-07-30
CN102149730A (zh) 2011-08-10
NZ602905A (en) 2014-05-30
JP2011527322A (ja) 2011-10-27
ZA201100209B (en) 2012-04-25
PT2315781E (pt) 2015-09-21
EP2315781A2 (fr) 2011-05-04
FR2933702A1 (fr) 2010-01-15
SI2315781T1 (sl) 2015-09-30
BRPI0915660A2 (pt) 2019-08-27
PL2315781T3 (pl) 2015-10-30
SG10201403751XA (en) 2014-09-26
HUE027221T2 (en) 2016-10-28
KR20110028536A (ko) 2011-03-18
CR11868A (es) 2011-02-16
MX2011000328A (es) 2011-04-05
HRP20150836T1 (hr) 2015-09-11
NZ590860A (en) 2012-12-21
ECSP11010748A (es) 2011-02-28
WO2010004204A3 (fr) 2010-04-29
PE20110313A1 (es) 2011-06-21
AR072699A1 (es) 2010-09-15
DOP2011000005A (es) 2011-02-15
AU2009267834A1 (en) 2010-01-14
ES2544761T3 (es) 2015-09-03

Similar Documents

Publication Publication Date Title
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201491550A1 (ru) Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201792520A3 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU